A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C

Molecular Psychiatry

Volumn 7, Issue 9, 2002, Pages 942-947

  Hauser, Peter ^a   Khosla, J ^b   Aurora, H ^b   Laurin, J ^b   Kling, M A ^b   Hill, J ^b   Gulati, M ^b   Thornton, A J ^a   Schultz, R L ^a   Valentine, A D ^c   Meyers, C A ^c   Howell, C D ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Citalopram; Hepatitis C; Interferon; Major depressive disorder

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; CITALOPRAM; INTERFERON; REBETRON; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; FEMALE; HEPATITIS C; HUMAN; INCIDENCE; MAJOR DEPRESSION; MALE; MIDDLE AGED; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME; BECK DEPRESSION INVENTORY; CONTROLLED STUDY; DEPRESSION; LIVER DISEASE; MAJOR CLINICAL STUDY; NEGRO; OUTCOMES RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIVIRAL AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; INTERFERONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036430340     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001119     Document Type: Article

References (35)

1. Alter M, Kruszon-Moran D, Nainan O, McQuillan G, Gao F, Moyer L et al. The prevalence of hepatitis C virus infection in the United States, 1988-1994. N Engl J Med 1999; 341: 556-562.
2. Fimmel C. Doing battle with HCV. Am J Gastroenterol 2000; 95: 582-583.
3. Koff R. Hepatitis C. In: Gorbach SB, Bartlett JG, Blacklow NR (eds). Infectious Diseases. 2nd Edn. WB Saunders: Philadelphia, 1998, pp 864-871.
4. Alter M. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S.
5. McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
6. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-438.
7. Lerner DM, Stoudemire A, Rosenstein DL. Neuropsychiatric toxicity associated with cytokine therapies. Psychosomatics 1999; 40: 428-435.
8. Yates WR, Gleason O. Hepatitis C and depression. Depress Anxiety 1998; 7: 188-193.
9. Valentine A, Meyers C, Kling M, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25 (Suppl 1): 39-47.
10. Bianchi G, Loguercio C, Sgarbi D, Abbiati R, Chen C, DiPierro M et al. Reduced quality of life in patients with chronic hepatitis C: Effects of interferon treatment. Dig Liver Dis 2000; 32: 398-405.
11. Hunt CM, Dominitz JA, Bute BP, Waters B, Blasi U, Williams DM. Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42: 2482-2486.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th Edn. APA: Washington, DC, 1994.
13. Trask P, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18: 2316-2326.
14. Zdilar D, Franco-Bronson K, Buchler N, Locala J, Younossi Z. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 1207-1211.
15. Dieperink E, Willenbring M, Ho S. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000; 157: 867-876.
16. Matsushita E, Unoura M, Kobayashi K. Psychiatric complications of interferon therapy. Nippon Rinsho 1994; 52: 1910-1913.
17. Miyaoka H, Otsubo T, Kamijima K, Ishii M, Onuki M, Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 1999; 156: 1120.
18. Yokoyama A, Kimura Y, Shigemura J. Psychiatric side effects of interferon. J Toxicol Sci 1996; 21: 93-96.
19. Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K. Depression during interferon therapy in chronic hepatitis C patients - A prospective study. Seishin Shinkeigaku Zasshi 1997; 99: 101-127.
20. Maddrey W. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C - Relapsed and treatment naive patients. Semin Liver Dis 1999; 19 (Suppl 1): 67-75.
21. Meyers C, Valentine A. Neurological and psychiatric adverse effects of immunological therapy. CNS Drugs 1995; 3: 56-68.
22. Renault P, Hoofnagle J, Park Y, Mullen K, Peters M, Jones B et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987; 147: 1577-1580.
23. Goldman L. Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomatics 1994; 35: 412-413.
24. Gleason O, Yates W. Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999; 40: 510-512.
25. Levenson J, Fallon H. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993; 88: 760-761.
26. Schramm T, Lawford B, Macdonald G, Cooksley W. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000; 173: 359-361.
27. Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J et al. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000; 41: 439-441.
28. Musselman D, Lawson D, Gumnick J, Manatunga A, Penna S, Goodkin R et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-966.
29. Tan J, Levin G. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999; 19: 675-689.
30. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0). New York State Psychiatric Institute New York NY, 1995.
31. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
32. Steer RA, Beck AT, Brown G, Berchick RJ. Self-reported depressive symptoms that differentiate recurrent-episode major depression from dysthymic disorders. J Clin Psychol 1987; 43: 246-250.
33. Hauser P, Thornton AJ, Schultz RL, Lewy AJ. A prospective study of the characteristics and time course of interferon-induced major depressive episodes in patients with hepatitis C. In: 40th Annual Conference of the American College of Neuropsychopharmacology, 2001. Waikoloa Village, HI, 2001.
34. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 1999; 340: 1370.
35. Janssen H, Brouwer J, van der Mast R, Schalm S. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21: 241-243.